Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Probable ticlopidine-induced cholestatic hepatitis

L J Cassidy1, B G Schuster, L S Halparin

  • 1Department of Pharmacy, St. Paul's Hospital, Vancouver, British Columbia, Canada.

The Annals of Pharmacotherapy
|January 1, 1995
PubMed
Summary

Ticlopidine can cause cholestatic hepatitis, a liver injury. Patients should monitor for jaundice and discontinue the drug if symptoms arise.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of endotoxin on thin lipid bilayer membranes.

The Journal of membrane biology·2013
Same author

Pollution plume transport and diffusion studies using fluorescence lidar.

Applied optics·2010
Same author

Secondary laser cavity for weak absorptions.

Applied optics·2010
Same author

Separation of dust and molecular scattering contributions to the lidar observation: a method.

Applied optics·2010
Same author

Detection and sizing of small particles in an open cavity gas laser.

Applied optics·2010
Same author

Constituents of Peucedanum zenkeri seeds and their antimicrobial effects.

Die Pharmazie·2003

Area of Science:

  • Hepatology
  • Clinical Pharmacology

Background:

  • Ticlopidine is an antiplatelet medication.
  • Drug-induced liver injury is a significant concern in clinical practice.

Observation:

  • A 76-year-old male developed painless jaundice three weeks after initiating ticlopidine therapy.
  • The patient had no prior history of liver disease.

Findings:

  • The jaundice and abnormal liver enzymes resolved after discontinuing ticlopidine.
  • A review of literature identified seven additional cases of ticlopidine-induced cholestatic hepatitis.

Implications:

  • While routine liver enzyme monitoring is not advised, patients should be aware of potential liver injury symptoms.
  • Prompt discontinuation of ticlopidine and medical consultation are crucial if signs of liver injury appear.

Related Experiment Videos